Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 23;8(47):eabn0238. doi: 10.1126/sciadv.abn0238

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 6. — (A) Cox regression HRs for hypertranscriptional patients across 20 tumor types. Hypertranscriptional patients have consistently worse overall survival. In six tumor types, hypertranscription acts as an independent prognostic factor (red bars indicate Cox-HR, P < 0.05). (B to G) Kaplan-Meier survival plots (left) and Cox regression model HRs (right) for (B) uterus carcinosarcoma, (C) sarcoma, (D) myxofibrosarcoma and undifferentiated pleomorphic sarcoma (MFS/UPS), (E) dedifferentiated liposarcoma (DDLPS), (F) luminal A BRCA, and (G) HPV⁺ HNSC. Only Kaplan-Meier plots are shown for patients with MFS/UPS sarcoma and luminal A BRCA, as all hypotranscriptional patients survive preventing analysis by Cox regression. Error bars on all HR coefficients represent the 95% CI. NA, not applicable.